Spyre Therapeutics
SYRE
SYRE
59 hedge funds and large institutions have $140M invested in Spyre Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
59
Holders Change
-5
Holders Change %
-7.81%
% of All Funds
1.35%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
23
Reduced
17
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.01M |
| 2 |
O
OrbiMed
New York
|
+$2.87M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.54M |
| 4 |
BlackRock
New York
|
+$1.98M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.38M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$5.04M |
| 2 |
SFM
Soros Fund Management
New York
|
-$2.18M |
| 3 |
SI
SCP Investment
Orinda,
California
|
-$1.65M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.42M |
| 5 |
JPMorgan Chase & Co
New York
|
-$711K |
